<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a2db0147-6adc-4672-b444-ae71a8d0b9b0,g:a298b67a-a5d7-4c2b-bcca-8d2a7e14a0a8,d:24498eae992544c4982a5b2f6fa4d1c4--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zsan-20201112</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF80L2ZyYWc6MjgzODIyZDMyOTM3NGQyYzkwMTg1ZjVmM2U1ZjQ0YjYvdGFibGU6YzZkZjQ2ODVkNjI5NDYzMzk2MzM1ZDQ0YmJlNWFmNTUvdGFibGVyYW5nZTpjNmRmNDY4NWQ2Mjk0NjMzOTYzMzVkNDRiYmU1YWY1NV8wLTEtMS0xLTA_231a22f3-7346-477b-be6d-8cc35b9ee14f">0001587221</ix:nonNumeric><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF80L2ZyYWc6MjgzODIyZDMyOTM3NGQyYzkwMTg1ZjVmM2U1ZjQ0YjYvdGFibGU6YzZkZjQ2ODVkNjI5NDYzMzk2MzM1ZDQ0YmJlNWFmNTUvdGFibGVyYW5nZTpjNmRmNDY4NWQ2Mjk0NjMzOTYzMzVkNDRiYmU1YWY1NV8xLTEtMS0xLTA_37a8748f-d763-4840-9bb7-97e9eeb5963f">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zsan-20201112.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001587221</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i24498eae992544c4982a5b2f6fa4d1c4_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzgx_6ee8ba1c-adb0-4366-a096-84fe8db88884">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8yMzI_3fac9095-3694-4cdd-bdd1-6d80acfdbeff">NOVEMBER 12, 2020</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzgy_ccd93c24-15ab-449b-9d32-121dec15f489">ZOSANO PHARMA CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:27.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6MWYxYmI1YzZjNWY2NDYzOWJkYTdkYjdjMjBiMGJmZDkvdGFibGVyYW5nZToxZjFiYjVjNmM1ZjY0NjM5YmRhN2RiN2MyMGIwYmZkOV8wLTAtMS0xLTA_3dd8c437-81c4-47da-b77d-c780caf5d2e0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6MWYxYmI1YzZjNWY2NDYzOWJkYTdkYjdjMjBiMGJmZDkvdGFibGVyYW5nZToxZjFiYjVjNmM1ZjY0NjM5YmRhN2RiN2MyMGIwYmZkOV8wLTItMS0xLTA_b6056b68-e457-49e7-a217-5a867984c23c">001-36570</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6MWYxYmI1YzZjNWY2NDYzOWJkYTdkYjdjMjBiMGJmZDkvdGFibGVyYW5nZToxZjFiYjVjNmM1ZjY0NjM5YmRhN2RiN2MyMGIwYmZkOV8wLTQtMS0xLTA_e810906c-2dc0-4df5-a490-e2d8f3d8abdc">45-4488360</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzg0_5b5a98c6-a86f-46e6-af94-ee3912cffed9">34790 Ardentech Court</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzc1_cb9cd944-f7ae-4393-80ce-39bb6446e54b">Fremont</ix:nonNumeric>, <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzc2_3bfdd01e-a8db-4205-aa50-c485537aff56">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzc5_02c00532-0cdc-44ca-a8e0-eff86335bc6c">94555</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV80MjQ_b6d9b26a-6fdc-45c2-97fc-bf3306ea01f1">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzc3_21e458bc-7abb-47c9-96cd-5ac086760688">745-1200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.903%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6NDdkZDU3MWFlYmI3NDg0MmJmZTcyNmU5YWZkZDdkN2YvdGFibGVyYW5nZTo0N2RkNTcxYWViYjc0ODQyYmZlNzI2ZTlhZmRkN2Q3Zl8wLTAtMS0xLTA_6f7f3535-8d04-46bf-a86d-08f97d78fbab">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6NDdkZDU3MWFlYmI3NDg0MmJmZTcyNmU5YWZkZDdkN2YvdGFibGVyYW5nZTo0N2RkNTcxYWViYjc0ODQyYmZlNzI2ZTlhZmRkN2Q3Zl8yLTAtMS0xLTA_2eaa1921-e529-42d4-a53a-72f049c4acfe">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6NDdkZDU3MWFlYmI3NDg0MmJmZTcyNmU5YWZkZDdkN2YvdGFibGVyYW5nZTo0N2RkNTcxYWViYjc0ODQyYmZlNzI2ZTlhZmRkN2Q3Zl80LTAtMS0xLTA_0d458bbe-73c3-4ef9-9b04-39e075ac78a2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6NDdkZDU3MWFlYmI3NDg0MmJmZTcyNmU5YWZkZDdkN2YvdGFibGVyYW5nZTo0N2RkNTcxYWViYjc0ODQyYmZlNzI2ZTlhZmRkN2Q3Zl82LTAtMS0xLTA_8e700b48-d99e-4bf5-8988-06cfb33c7470">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-bottom:14pt;margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:32.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6YTFhNzEyOTk1MTJkNGViNThjZGViYTFiYmUwZDFiM2EvdGFibGVyYW5nZTphMWE3MTI5OTUxMmQ0ZWI1OGNkZWJhMWJiZTBkMWIzYV8xLTAtMS0xLTA_32f563ee-35a6-4677-9f73-165d36b6da52">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6YTFhNzEyOTk1MTJkNGViNThjZGViYTFiYmUwZDFiM2EvdGFibGVyYW5nZTphMWE3MTI5OTUxMmQ0ZWI1OGNkZWJhMWJiZTBkMWIzYV8xLTEtMS0xLTA_86c10b21-2e12-4135-8df1-50994ad254b6">ZSAN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGFibGU6YTFhNzEyOTk1MTJkNGViNThjZGViYTFiYmUwZDFiM2EvdGFibGVyYW5nZTphMWE3MTI5OTUxMmQ0ZWI1OGNkZWJhMWJiZTBkMWIzYV8xLTItMS0xLTA_df55c787-380b-4dbb-a941-a4a5e1c73bcd">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzgw_8647070e-d2ce-4d0d-91f5-0e3b06fc95b1">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;  <ix:nonNumeric contextRef="i3b1b0a53c2234e18a0de0ecb2e97aa2c_D20201112-20201112" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NDk4ZWFlOTkyNTQ0YzQ5ODJhNWIyZjZmYTRkMWM0L3NlYzoyNDQ5OGVhZTk5MjU0NGM0OTgyYTViMmY2ZmE0ZDFjNF8xL2ZyYWc6ZWZjMzQyMWM4N2YyNGE4Njg3OGQ4MmJlMGU0MjZmMWUvdGV4dHJlZ2lvbjplZmMzNDIxYzg3ZjI0YTg2ODc4ZDgyYmUwZTQyNmYxZV8xMzc4_a1ca8ef8-da1b-4e90-8f7f-8a5f2d45dd78">&#9746;</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i24498eae992544c4982a5b2f6fa4d1c4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 13, 2020, Zosano Pharma Corporation (the "Company") issued a press release titled &#8220;Zosano Pharma Reports Third Quarter 2020 Financial Results.&#8221; The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.01    &#160;&#160;&#160;&#160;Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                     </span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company received written notice from The Nasdaq Stock Market, LLC (&#8220;Nasdaq&#8221;) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until May 11, 2021, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is not in compliance by May 11, 2021, the Company may be eligible for additional time to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal Nasdaq's determination, but there can be no assurance that Nasdaq would grant the Company's request for continued listing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;text-decoration:underline">Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q320exhibit991.htm">Press release dated November 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q320exhibit991.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q320exhibit991.htm">, 2020, titled &#8220;Zosano Pharma Reports Third  Quarter 2020 Financial Results&#8221;</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="i24498eae992544c4982a5b2f6fa4d1c4_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:41.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.843%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ZOSANO PHARMA CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 13, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christine Matthews</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Christine Matthews</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: &#160;&#160;Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "zsan-20201112.htm", "description": "8-K", "secsgml_size_bytes": 41841}]
{"company-data": {"conformed-name": "Zosano Pharma Corp", "cik": "0001587221", "assigned-sic": "2834", "irs-number": "454488360", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36570", "film-number": "201311542"}, "business-address": {"street1": "34790 ARDENTECH COURT", "city": "FREMONT", "state": "CA", "zip": "94555", "phone": "510-745-1200"}, "mail-address": {"street1": "34790 ARDENTECH COURT", "city": "FREMONT", "state": "CA", "zip": "94555"}, "former-company": {"former-conformed-name": "ZP Holdings Inc", "date-changed": "20130919"}}
zsan-20201112
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
NOVEMBER 12, 2020
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-36570
45-4488360
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
34790 Ardentech Court
Fremont
,
CA
94555
(Address of principal executive offices) (Zip Code)
(
510
)
745-1200
Registrant's telephone number, including area code
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value
ZSAN
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 2.02    Results of Operations and Financial Condition.
On November 13, 2020, Zosano Pharma Corporation (the "Company") issued a press release titled "Zosano Pharma Reports Third Quarter 2020 Financial Results." The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 3.01        Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 12, 2020, the Company received written notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until May 11, 2021, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.
If the Company is not in compliance by May 11, 2021, the Company may be eligible for additional time to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency.
If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal Nasdaq's determination, but there can be no assurance that Nasdaq would grant the Company's request for continued listing.
The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price requirement. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.
Item 9.01    Financial Statements and Exhibits.
(d)
Exhibits
.
Exhibit
Description
99.1
Press release dated November 1
3
, 2020, titled "Zosano Pharma Reports Third  Quarter 2020 Financial Results"
104.1
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZOSANO PHARMA CORPORATION
Date: November 13, 2020
By:
/s/ Christine Matthews
Name: Christine Matthews
Title:   Chief Financial Officer